<span item_type="fundamental" item_id="9fe6cd53101e24d85c4ef83bd61a932c" counter_id="ST/US/CINGW" env="prod"></span><span item_type="announcement" item_id="551144482296891777" env="prod"></span><p>EBIT: As of FY2025 Q2, the actual value is USD -4.65 M.</p><p></p><h3>Cash and Working Capital</h3><p>As of June 30, 2025, Cingulate had approximately $8.9 million in cash and cash equivalents, a decrease of $3.3 million from December 31, 2024. The company expects its cash will satisfy its capital needs into late 2025 under the current business plan. To advance the commercialization efforts for CTx-1301 into early 2026, the company will need to raise approximately $1.5 million of additional capital.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024741/ex99-1.htm"></span></p><h3>Research and Development Expenses</h3><p>Research and development expenses were $2.7 million for the three months ended June 30, 2025, an increase of $0.8 million or 43.6% from the same period in 2024. This increase was due to higher clinical and regulatory costs related to the NDA submission of CTx-1301, partially offset by a decrease in manufacturing costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024741/ex99-1.htm"></span></p><h3>General and Administrative Expenses</h3><p>General and administrative expenses were $1.9 million for the three months ended June 30, 2025, an increase of $0.6 million or 47.1% from the same period in 2024, primarily due to higher legal and financial advisory fees.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024741/ex99-1.htm"></span></p><h3>Net Loss</h3><p>Net loss was $4.8 million for the three months ended June 30, 2025, compared to $3.2 million for the same period in 2024. The increase in net loss was primarily due to increased research and development costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024741/ex99-1.htm"></span></p><h3>Outlook / Guidance</h3><p>Cingulate anticipates an FDA decision in Q4 2025 regarding the NDA acceptance for CTx-1301, with a potential PDUFA date in mid-2026. The company plans to prioritize pre-commercial activities in anticipation of the launch of CTx-1301 in mid-2026, pending FDA approval.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225024741/ex99-1.htm"></span></p>

CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 8-K: FY2025 Q2 EBIT: USD -4.65 M